LabCorp announced the launch of a test to simultaneously detect COVID-19, influenza A / B, and respiratory syncytial virus (RSV), according to a press release.
The single-panel test, which detects multiple types of infections, is available to patients through doctors, hospitals, and other authorized healthcare providers nationwide.
LabCorp has also submitted an application to the U.S. Food and Drug Administration (FDA) to offer the combined test through its Pixel by LabCorp at-home test collection kit, which would offer added convenience and accessibility. Earlier this year, the FDA granted an EUA to LabCorp to use the Pixel by LabCorp at-home kit to collect specimens for COVID-19 if recommended by a healthcare provider after patients complete a COVID-19 questionnaire. The Pixel by LabCorp at-home test uses a short swab that is easily inserted into the individual’s lower nostril, reducing the discomfort associated with much longer swabs.
